Physician profile
Henry Adkins
NPI 1578669297
$2,198.71
in general payments reported to CMS, 2019-2025
25 companies · $773 in 2025
The $773 reported for 2025 was more than what 81% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $171 · 2023: $404 · 2024: $851 · 2025: $773.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,027.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,027.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $325.45 | 2024-2025 | Airsupra, Farxiga, Breztri |
| Novo Nordisk INC | $220.48 | 2024-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $197.16 | 2022-2024 | Jardiance, Mounjaro, Trulicity |
| Abbvie INC. | $195.31 | 2023-2025 | Vraylar, Viberzi, Linzess |
| Dexcom, INC. | $150.89 | 2023-2025 | Dexcom G6 Transmitter |
| Glaxosmithkline, LLC. | $143.01 | 2022-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Mylan Specialty L.P. | $135.22 | 2023-2024 | Yupelri |
| Exact Sciences Corporation | $122.74 | 2023-2025 | Cologuard Collection Kit |
| Corcept Therapeutics | $96.89 | 2024-2025 | Korlym |
| Bayer Healthcare Pharmaceuticals INC. | $96.54 | 2022-2025 | |
| Pfizer INC. | $88.86 | 2023-2025 | |
| Novartis Pharmaceuticals Corporation | $75.03 | 2023-2025 | |
| Merck Sharp & Dohme LLC | $68.18 | 2023-2024 | Gardasil 9, Gardasil, Capvaxive |
| Averitas Pharma INC. | $38.62 | 2024-2025 | Qutenza |
| Otsuka America Pharmaceutical, INC. | $31.44 | 2023-2024 | Rexulti |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $30.92 | 2023-2024 | Otezla, Repatha |
| Xeris Pharmaceuticals, INC. | $30.54 | 2025 | Gvoke Hypopen |
| Noven Therapeutics, LLC | $24.99 | 2024 | Xelstrym |
| Viatris Specialty LLC | $23.03 | 2025 | Yupelri |
| Astellas Pharma US INC | $22.50 | 2024 | Veozah |
| Abbott Laboratories | $19.14 | 2025 | Freestyle Libre 3 |
| Nevro Corp. | $18.60 | 2023 | Senza |
| Currax Pharmaceuticals LLC | $15.49 | 2025 | Contrave |
| Phathom Pharmaceuticals, INC. | $14.41 | 2025 | Voquezna |
| Sonex Health, INC. | $13.27 | 2025 | Sx-One Microknife |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Henry Adkins listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.